643 related articles for article (PubMed ID: 34201655)
1. MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It.
Shklovskaya E; Rizos H
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201655
[TBL] [Abstract][Full Text] [Related]
2. Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation.
Dhatchinamoorthy K; Colbert JD; Rock KL
Front Immunol; 2021; 12():636568. PubMed ID: 33767702
[TBL] [Abstract][Full Text] [Related]
3. Cancer immune escape: MHC expression in primary tumours versus metastases.
Garrido F; Aptsiauri N
Immunology; 2019 Dec; 158(4):255-266. PubMed ID: 31509607
[TBL] [Abstract][Full Text] [Related]
4. MHC class I TCR engineered anti-tumor CD4 T cells: implications for cancer immunotherapy.
Chhabra A
Endocr Metab Immune Disord Drug Targets; 2009 Dec; 9(4):344-52. PubMed ID: 19807670
[TBL] [Abstract][Full Text] [Related]
5. MHC class I antigens, immune surveillance, and tumor immune escape.
Garcia-Lora A; Algarra I; Garrido F
J Cell Physiol; 2003 Jun; 195(3):346-55. PubMed ID: 12704644
[TBL] [Abstract][Full Text] [Related]
6. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape.
Algarra I; García-Lora A; Cabrera T; Ruiz-Cabello F; Garrido F
Cancer Immunol Immunother; 2004 Oct; 53(10):904-10. PubMed ID: 15069585
[TBL] [Abstract][Full Text] [Related]
7. MHC class I antigens and immune surveillance in transformed cells.
Aptsiauri N; Cabrera T; Garcia-Lora A; Lopez-Nevot MA; Ruiz-Cabello F; Garrido F
Int Rev Cytol; 2007; 256():139-89. PubMed ID: 17241907
[TBL] [Abstract][Full Text] [Related]
8. Tumour MHC class I downregulation and immunotherapy (Review).
Bubeník J
Oncol Rep; 2003; 10(6):2005-8. PubMed ID: 14534734
[TBL] [Abstract][Full Text] [Related]
9. MHC heterogeneity and response of metastases to immunotherapy.
Algarra I; Garrido F; Garcia-Lora AM
Cancer Metastasis Rev; 2021 Jun; 40(2):501-517. PubMed ID: 33860434
[TBL] [Abstract][Full Text] [Related]
10. MHC class II restricted neoantigen: A promising target in tumor immunotherapy.
Sun Z; Chen F; Meng F; Wei J; Liu B
Cancer Lett; 2017 Apr; 392():17-25. PubMed ID: 28104443
[TBL] [Abstract][Full Text] [Related]
11. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.
Kim N; Kim HS
Front Immunol; 2018; 9():2041. PubMed ID: 30250471
[TBL] [Abstract][Full Text] [Related]
12. Naked RNA vaccine controls tumors with down-regulated MHC class I expression through NK cells and perforin-dependent pathways.
Cheng WF; Hung CF; Lee CN; Su YN; Chang MC; He L; Wu TC; Chen CA; Hsieh CY
Eur J Immunol; 2004 Jul; 34(7):1892-900. PubMed ID: 15214037
[TBL] [Abstract][Full Text] [Related]
13. MHC class I down-regulation: tumour escape from immune surveillance? (review).
Bubeník J
Int J Oncol; 2004 Aug; 25(2):487-91. PubMed ID: 15254748
[TBL] [Abstract][Full Text] [Related]
14. Forcing tumor cells to present their own tumor antigens to the immune system: a necessary design for an efficient tumor immunotherapy.
Humphreys RE; Hillman GG; von Hofe E; Xu M
Cell Mol Immunol; 2004 Jun; 1(3):180-5. PubMed ID: 16219165
[TBL] [Abstract][Full Text] [Related]
15. Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing.
Leclerc M; Mezquita L; Guillebot De Nerville G; Tihy I; Malenica I; Chouaib S; Mami-Chouaib F
Front Immunol; 2019; 10():1505. PubMed ID: 31333652
[TBL] [Abstract][Full Text] [Related]
16. "Hard" and "soft" lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy.
Garrido F; Cabrera T; Aptsiauri N
Int J Cancer; 2010 Jul; 127(2):249-56. PubMed ID: 20178101
[TBL] [Abstract][Full Text] [Related]
17. CD4+ T cells induce rejection of urothelial tumors after immune checkpoint blockade.
Sato Y; Bolzenius JK; Eteleeb AM; Su X; Maher CA; Sehn JK; Arora VK
JCI Insight; 2018 Dec; 3(23):. PubMed ID: 30518683
[TBL] [Abstract][Full Text] [Related]
18. Ex vivo-activated MHC-unrestricted immune effectors for cancer adoptive immunotherapy.
Leuci V; Mesiano G; Gammaitoni L; Todorovic M; Giraudo L; Carnevale-Schianca F; Aglietta M; Sangiolo D
Anticancer Agents Med Chem; 2014 Feb; 14(2):211-22. PubMed ID: 24237224
[TBL] [Abstract][Full Text] [Related]
19. TEIPP antigens for T-cell based immunotherapy of immune-edited HLA class I
Marijt KA; Doorduijn EM; van Hall T
Mol Immunol; 2019 Sep; 113():43-49. PubMed ID: 29627136
[TBL] [Abstract][Full Text] [Related]
20. Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC.
Neeley YC; McDonagh KT; Overwijk WW; Restifo NP; Sanda MG
Prostate; 2002 Nov; 53(3):183-91. PubMed ID: 12386918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
